After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

During the hearing, an official from Novo Nordisk will be questioned about the pricing they charge for Ozempic and ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Drug maker Novo Nordisk has landed in hot water in the UK over its promotional practices. Now RTÉ Investigates examines the company's links to medical experts in Ireland.

Novo Nordisk has today forecast another year of double-digit record sales and operating profit growth as it began easing restrictions on supply of its popular weight-loss drug Wegovy.

Diabetes and obesity drug developer Novo Nordisk on Thursday significantly raised its full-year operating profit and sales expectations on the back of strong demand for its highly popular Wegovy ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...